PanNASH™ initiative, a working group consisting of a committee of international independent experts that aims to increase the visibility and contribute to a better understanding of NASH (a multisystem disease), to share their expertise and to establish best practices for the treatment of the disease has been supported since three years by Inventiva S.A. a biopharmaceutical company developing innovative therapies in nonalcoholic steatohepatitis (NASH), systemic sclerosis (SSc) and mucopolysaccharidosis (MPS).
The committee, which is entirely funded by Inventiva, includes European, American and Asian medical experts in areas related to NASH such as hepatology, diabetes and cardiology, along with renowned scientific experts focused on promoting a better understanding of the physiopathological mechanisms involved in NASH (see the list of the founding members in PanNASH initiative web site – www.pannash.org). Their aim will therefore be to play an active role in developing and disseminating their NASH expertise among the scientific community, patients and other key stakeholders within the healthcare system.
In particular, the experts group intends to help develop and share new findings about NASH through scientific publications, conferences and training sessions. It will particularly focus on the development of the disease as a multi-system disease, the identification of patients at risk, clinical markers and associated health risks, as well as the development of new treatments. Specifically, the committee will help to increase knowledge of pathological mechanisms ranging from metabolic disorders to fibrosis and comorbidities, with a focus on the modulating role played by PPARs (peroxisome proliferator-activated receptors, α, δ, ɣ subtypes).